Psilocybin
Psyched Wellness Names Gotham Green Board Member
Gotham Green got the placement after buying stock in the offering.
The post Psyched Wellness Names Gotham Green Board Member appeared first on Green Market…
Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) announced that Amanda Galbraith has resigned as a director of the company effective June 19, 2023. She has been replaced with Gotham Green’s Harrison Aaron who was appointed as director effective June 19, 2023.
“Psyched Wellness’s work over the past four years has been ground-breaking, with the company developing its proprietary extract of the federally legal Amanita Muscaria mushroom, AME-1, and proving its safety for human consumption through extensive studies and United States GRAS certification. With this proposed investment, we would aim to fund and facilitate the nationwide rollout of mainstream consumer products centered around AME-1, and we look forward to working closely with the company,” said Harrison Aaron, Principal at Gotham Green Partners.
Gotham Green was allowed to name a board member after Psyched announced that it had closed the initial tranche of its non-brokered private placement. The company issued 9,585,000 units at a price of C$0.07 per unit for gross proceeds of $500,000, approximately C$670,950, based on an exchange rate of US$1.00 = C$1.3419 as at June 6, 2023, as published on the website of the Bank of Canada. Psyched has said it will use the money for general working purposes.
The board also favors offering a second tranche that will raise $7 million. If tranche two closes, Gotham will have the right to designate two additional directors to become members of the Board who would replace existing Board members. Gotham could end up having three board members out of a total of seven board members. Nick Kadysh is expected to be named a board member in the next level of additions. Any units bought in tranche two will be subject to a 12 month lockup period.
Going Concern
For the quarter ending February 28, 2023, Psyched Wellness reported a net and comprehensive loss of C$1,012,962 (2022 – C$1,356,433) and negative cash flow from operations of C$814,226 (2022 – C$736,086), and as of that date, its accumulated deficit was C$23,539,182 (November 30, 2022 – $23,679,183). The company’s cash at the end of the quarter had fallen to C$1.6 million. The company’s current liabilities at the time were C$435,207
The post Psyched Wellness Names Gotham Green Board Member appeared first on Green Market Report.
amanita amanita muscaria mushroom private placement fund cse psyched wellness psyched psyc
-
Psychedelics6 days agoAlgernon NeuroScience and the Centre for Human Drug Research to Present DMT Phase 1 Stroke Clinical Data at the Interdisciplinary Conference on Psychedelic Research June 6 – 8th, 2024
-
Psychedelics1 week agoRevive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID
-
Psilocybin1 week agoPassover Perspectives: Psychedelics, Moses, and the Burning Bush
-
Law & Regulation6 days agoTryp Therapeutics merger with Exopharm approved by shareholders
-
Psychedelics6 days agoatai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech’s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression
-
Psychedelics1 week agoSilo Pharma Announces Positive Results for Intranasal PTSD Treatment
-
Psilocybin1 week agoPsilocybin and Meditation: Unlocking the Potential for Enhancing Insightfulness
-
Psychedelics1 week agoRed Light Holland Initiates Psilocybin Extraction Phase with PharmAla Following Successful Testing and Preparation by CCrest Labs